Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 1;12(6):941-944.
doi: 10.21037/hbsn-23-538. Epub 2023 Nov 9.

An ever-increasing metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: what are problems and countermeasures?

Shigeo Shimose  1 , Tsubasa Tsutsumi  1 , Dan Nakano  1 , Tomoya Sano  1 , Keisuke Amano  1 , Takumi Kawaguchi  1
Affiliations
Editorial

An ever-increasing metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: what are problems and countermeasures?

Shigeo Shimose et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Hepatoma; hepatic steatosis; lenvatinib (LEN); metabolic syndrome; viral hepatitis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-538/coif). T.K. received lecture fees from Eisai Co., Ltd., Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., AbbVie GK., and EA Pharma Co., Ltd. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
A scheme for an ever-increasing MAFLD related HCC and its problems and countermeasures. MAFLD, metabolic dysfunction-associated fatty liver disease; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus.
See this image and copyright information in PMC

Comment on

  • Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Vitale A, et al. Gut. 2023 Jan;72(1):141-152. doi: 10.1136/gutjnl-2021-324915. Epub 2021 Dec 21. Gut. 2023. PMID: 34933916

References

    1. Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2023;72:141-52. 10.1136/gutjnl-2021-324915 - DOI - PubMed
    1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9. 10.1016/j.jhep.2020.03.039 - DOI - PubMed
    1. Kawaguchi T, Tsutsumi T, Nakano D, et al. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2022;52:422-32. 10.1111/hepr.13706 - DOI - PubMed
    1. Kawaguchi T, Tsutsumi T, Nakano D, et al. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol 2022;28:150-63. 10.3350/cmh.2021.0310 - DOI - PMC - PubMed
    1. Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 2021;51:1115-28. 10.1111/hepr.13685 - DOI - PubMed